I-Corps: An adjuvant to improve the safety and tolerability of stimulant medications

这个I-Corps项目更广泛的影响/商业潜力是开发一种佐剂技术，可以与兴奋剂药物化学结合，以提高安全性和耐受性。 兴奋剂药物，如d-苯丙胺，是用于治疗一系列精神和神经疾病的强效药物，如注意力缺陷多动障碍（ADHD），暴食症和抑郁症。 然而，对这些化合物成瘾的风险限制了它们的效用。 这限制了医生开这些药物的意愿，而缉毒局对这些化合物的安排也限制了他们的处方。 该技术使用神经科学指导的方法来消除奖励性质并消除兴奋剂药物的滥用倾向，同时增强其治疗效果。 此外，该技术还可以应用于阿片类药物，以同时增强其镇痛作用并防止成瘾。这项技术有可能提高那些处方兴奋剂药物的治疗依从性和结果。这个I-Corps项目是基于开发一种药理学佐剂，限制兴奋剂药物的滥用倾向。所提出的技术可用于开发具有低滥用倾向或无滥用倾向的一类新药。 迄今为止收集的数据表明，该技术还可以增强兴奋剂药物对某些适应症的治疗效果。此外，概念验证研究表明，拟议的佐剂可以与兴奋剂和阿片类药物共同配制，而不会影响其稳定性，提供了一种平台技术，可以很容易地应用于改善许多现有药物的安全性。 该技术可应用于提高一系列精神和神经适应症的兴奋剂药物治疗的安全性和耐受性。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of an adjuvant technology that can be chemically combined with stimulant medications to enhance safety and tolerability. Stimulant drugs, such as d-amphetamine, are powerful medications that are used to treat a range of psychiatric and neurological conditions, such as attention deficit hyperactivity disorder (ADHD), binge eating disorder, and depression. However, the risk of developing addiction to these compounds limits their utility. This limits physicians’ willingness to prescribe these drugs, and the Drug Enforcement Administration's scheduling of these compounds also limits their prescription. The proposed technology uses a neuroscience-guided approach to eliminate the rewarding properties and remove abuse liability of stimulant medications while enhancing their therapeutic effects. In addition, the proposed technology also may be applied to opioids to simultaneously enhance their analgesic effects and protect against addiction. This technology has the potential to improve treatment adherence and outcomes for those prescribed stimulant medications.This I-Corps project is based on the development of a pharmacological adjuvant that limits the abuse liability of stimulant medications. The proposed technology may be used to develop a new class of medications with low or no abuse liability. Data collected to date indicate that the technology also can enhance the therapeutic efficacy of stimulant medications for some indications. In addition, proof-of-concept studies indicate that the proposed adjuvant can be co-formulated with stimulants and opioids without affecting their stability, providing a platform technology that may be readily applied to improve the safety profile of many existing medications. The proposed technology may have applications to enhance the safety and tolerability for treatment with stimulant medications for a range of psychiatric and neurological indications.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.